A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe

Seidu S., Cos X., Brunton S., Harris S., Jansson S., Mata-Cases M., ...Daha Fazla

Primary Care Diabetes, cilt.15, sa.1, ss.31-51, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 15 Sayı: 1
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.pcd.2020.05.004
  • Dergi Adı: Primary Care Diabetes
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.31-51
  • Anahtar Kelimeler: Type 2 diabetes, Cardiovascular disease, Cardiovascular risk factors, Multimorbidity, Therapeutic inertia, Heart failure, Chronic kidney disease, Elderly, Primary care, Patient-centred care, Shared decision making, BLOOD-GLUCOSE CONTROL, INTENSIVE MULTIFACTORIAL THERAPY, GLUCAGON-LIKE PEPTIDE-1, CORONARY-HEART-DISEASE, LONG-TERM EFFICACY, 10-YEAR FOLLOW-UP, ADD-ON THERAPY, CARDIOVASCULAR OUTCOMES, DOUBLE-BLIND, GLYCEMIC CONTROL
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Type 2 diabetes and its associated comorbidities are growing more prevalent, and the complexity of optimising glycaemic control is increasing, especially on the frontlines of patient care. In many countries, most patients with type 2 diabetes are managed in a primary care setting. However, primary healthcare professionals face the challenge of the growing plethora of available treatment options for managing hyperglycaemia, leading to difficultly in making treatment decisions and contributing to therapeutic inertia. This position statement offers a simple and patient-centred clinical decision-making model with practical treatment recommendations that can be widely implemented by primary care clinicians worldwide through shared-decision conversations with their patients. It highlights the importance of managing cardiovascular disease and elevated cardiovascular risk in people with type 2 diabetes and aims to provide innovative risk stratification and treatment strategies that connect patients with the most effective care. (C) 2020 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.